Photofrin Related Published Studies
Well-designed clinical trials related to Photofrin (Porfimer)
ALA and Photofrin(R) Fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial. [2008.10]
ALA and Photofrin(R) Fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial. [2007.10.10]
Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. [2005.10]
A multispectral fluorescence imaging system: design and initial clinical tests in intra-operative Photofrin-photodynamic therapy of brain tumors. [2003]
Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. [1995.12]
Effect of N-acetylcysteine on Photofrin-induced skin photosensitivity in patients. [1995]
Well-designed clinical trials possibly related to Photofrin (Porfimer)
[BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study] [2009.03]
Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness. [2005.07]
Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. [2003.11]
Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. [2003.07]
Biodistribution of three photosensitizers in dogs with spontaneous tumors. [2003.06]
Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation. [2000.09]
Effect of photodynamic therapy on recurrent pituitary adenomas: clinical phase I/II trial--an early report. [2000.08]
Effect of photodynamic therapy on revascularization of fasciocutaneous flaps. [2000.06]
Efficacy and safety of photodynamic therapy versus Nd-YAG laser resection in NSCLC with airway obstruction. [1999.10]
Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results. [1998.07]
Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. [1997.12]
Photodynamic therapy for obstructing esophageal cancer: light dosimetry and randomized comparison with Nd:YAG laser therapy. [1995.07]
Other research related to Photofrin (Porfimer)
Photodynamic therapy using intra-articular Photofrin for murine MRSA arthritis: biphasic light dose response for neutrophil-mediated antibacterial effect. [2011.03]
The pharmacokinetics and safety of porfimer after repeated administration 30-45 days apart to patients undergoing photodynamic therapy. [2010.09]
TP53 regulates human AlkB homologue 2 expression in glioma resistance to Photofrin-mediated photodynamic therapy. [2010.07.27]
PHOTOFRIN-mediated photodynamic therapy for treatment of early stage (Tis-T2N0M0) SqCCa of oral cavity and oropharynx. [2010.01]
Identification of MAP kinase pathways involved in COX-2 expression following photofrin photodynamic therapy. [2010]
Fluence rate-dependent intratumor heterogeneity in physiologic and cytotoxic responses to Photofrin photodynamic therapy. [2009.12]
The characterization of blood flow changes in mouse tumor during Photofrin-based photodynamic therapy by using the color Doppler ultrasonography. [2009.11]
Antitumor effect of photodynamic therapy in mice using direct application of Photofrin dissolved in lidocaine jelly. [2009.10]
Photofrin PDT for early stage oesophageal cancer: long term results in 40 patients and literature review. [2009.09]
Effect of drug-light interval on the mode of action of Photofrin photodynamic therapy in a mouse tumor model. [2009.07]
Mechanism of photofrin-enhanced ultrasound-induced human glioma cell death. [2009.03]
Increased tumour dihydroceramide production after Photofrin-PDT alone and improved tumour response after the combination with the ceramide analogue LCL29. Evidence from mouse squamous cell carcinomas. [2009.02.24]
Cranial neuropathies after intracranial Photofrin-photodynamic therapy for malignant supratentorial gliomas-a report on 3 cases. [2008.08]
Photofrin photodynamic therapy: 2.0 mg/kg or not 2.0 mg/kg that is the question. [2008.06]
In vitro and in vivo photosensitizing applications of Photofrin in malignant melanoma cells. [2008.05]
Anti-tumor effect of PDT using Photofrin in a mouse angiosarcoma model. [2008.04]
Comparison of photodynamic therapy with phthalocyanine and photofrin in human colorectal carcinoma. [2008]
Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. [2007.09]
Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. [2007.07.20]
Buried dysplasia and early adenocarcinoma arising in barrett esophagus after porfimer-photodynamic therapy. [2007.03]
In vitro behavior of Porfimer sodium and Talaporfin sodium with high intensity pulsed irradiation. [2006.12]
Feasibility of photofrin II as a radiosensitizing agent in solid tumors--preliminary results. [2006.11]
Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy. [2006.09.15]
A dose ranging study of photodynamic therapy with porfimer sodium (Photofrin) for treatment of basal cell carcinoma. [2006.06]
Porfimer sodium photodynamic therapy for management of Barrett's esophagus with high-grade dysplasia. [2006.06]
Simultaneous two-photon excitation of photofrin in relation to photodynamic therapy. [2006.03]
Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299). [2006.03]
Changes in esophageal motility after porfimer sodium photodynamic therapy for Barrett's dysplasia and mucosal carcinoma. [2006]
Lack of effect of sex and disease state on the pharmacokinetics of porfimer sodium. [2006]
The Application of Photofrin II as a sensitizing agent for ionizing radiation--a new approach in tumor therapy? [2005]
Photobleaching kinetics of Photofrin in vivo and in multicell tumour spheroids indicate two simultaneous bleaching mechanisms. [2004.11.07]
Sonodynamic therapy on chemically induced mammary tumor: pharmacokinetics, tissue distribution and sonodynamically induced antitumor effect of porfimer sodium. [2004.09]
Quantification of in vivo Photofrin uptake by human pituitary adenoma tissue. [2004.08]
Evaluation of porfimer sodium in dogs and cats with spontaneous tumors. [2004.03]
[Clinical study of Photofrin photodynamic therapy for advanced cancers] [2003.12]
Liposomal photofrin enhances therapeutic efficacy of photodynamic therapy against the human gastric cancer. [2003.11.30]
Photofrin as a radiosensitizer in an in vitro cell survival assay. [2003.11.07]
Hyperoxygenation enhances the tumor cell killing of photofrin-mediated photodynamic therapy. [2003.11]
Sonodynamic therapy with photofrin II on AH130 solid tumor. Pharmacokinetics, tissue distribution and sonodynamic antitumoral efficacy of photofrin II. [2003.02]
Photodynamic therapy with photofrin in combination with Buthionine Sulfoximine (BSO) of human glioma in the nude rat. [2003]
Application of Photofrin II as a specific radiosensitising agent in patients with bladder cancer--a report of two cases. [2002.09]
Radiation therapy combined with photofrin or 5-ALA: effect on Lewis sarcoma tumor lines implanted in mice. Preliminary results. [2002.09]
Photofrin as a specific radiosensitizing agent for tumors: studies in comparison to other porphyrins, in an experimental in vivo model. [2002.04]
Photodynamic effects on rabbit auricular veins after photosensitization with porfimer sodium: Implications of the results with respect to the treatment of esophageal varices with photodynamic therapy. [2002.03]
In vitro and in vivo efficacy of photofrin and pheophorbide a, a bacteriochlorin, in photodynamic therapy of colonic cancer cells. [2002.02]
Photodynamic therapy with photofrin reduces invasiveness of malignant human glioma cells. [2002]
IL-10 does not play a role in cutaneous Photofrin photodynamic therapy-induced suppression of the contact hypersensitivity response. [2001.12]
Analysis of photosensitivity in Japanese cancer-bearing patients receiving photodynamic therapy with porfimer sodium (Photofrin). [2001.10]
Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts. [2001.08.01]
Comparison of the in vivo efficiency of photofrin II-, mTHPC-, mTHPC-PEG- and mTHPCnPEG-mediated PDT in a human xenografted head and neck carcinoma. [2001]
PHOTOFRIN-mediated photodynamic therapy for treatment of early stage oral cavity and laryngeal malignancies. [2001]
Cellular distribution and phototoxicity of benzoporphyrin derivative and Photofrin. [2000.06]
Potentiation of the anti-tumour effects of Photofrin-based photodynamic therapy by localized treatment with G-CSF. [2000.04]
Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate. [2000.02.01]
Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi's sarcoma. [1999.09.10]
Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model. [1999.09.01]
Short- and long-term normal tissue damage with photodynamic therapy in pig trachea: a fluence-response pilot study comparing Photofrin and mTHPC. [1999.05]
Photodynamic therapy of atherosclerosis using YAG-OPO laser and Porfimer sodium, and comparison with using argon-dye laser. [1999.04]
In vivo resistance to photofrin-mediated photodynamic therapy in radiation-induced fibrosarcoma cells resistant to in vitro Photofrin-mediated photodynamic therapy. [1999.04]
Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group. [1998.07]
Clinical photodynamic therapy for superficial cancer in the oesophagus and the bronchi: 514 nm compared with 630 nm light irradiation after sensitization with Photofrin II. [1998.06]
Photodynamic therapy for facial squamous cell carcinoma in cats using Photofrin. [1998.03]
Photodynamic therapy using Photofrin in combination with buthionine sulfoximine (BSO) to treat 9L gliosarcoma in rat brain. [1998]
Photodynamic therapy for gastrointestinal tumors using three photosensitizers--ALA induced PPIX, Photofrin and MTHPC. A pilot study. [1998]
The effects of thrombocytopenia on vessel stasis and macromolecular leakage after photodynamic therapy using photofrin. [1997.10]
Influence of Photofrin on the hematopoietic accessory function of murine peritoneal cells. [1997.08]
Photofrin-mediated photodynamic therapy of chemically-induced premalignant lesions and squamous cell carcinoma of the palatal mucosa in rats. [1997.06]
Elimination of adult T cell leukemia cells by ultrasound in the presence of porfimer sodium. [1997.04]
Photodynamic therapy of 9L gliosarcoma with liposome-delivered photofrin. [1997.04]
Intraoperative phototherapy: a comparative study of intravenous and topical photofrin II and aminolevulinic acid. [1997.02]
Acute immediate urticarialike reaction to i.v. injected photofrin. [1997]
A preliminary pharmacokinetic study of intravenous Photofrin in patients. [1996.10]
Evidence for different mechanisms of EMT-6 tumor necrosis by photodynamic therapy with disulfonated aluminum phthalocyanine or photofrin: tumor cell survival and blood flow. [1996.07]
Cytotoxic effect of photodynamic therapy with Photofrin II on intimal hyperplasia. [1996.05]
Influence of fractionation and fluence rate in photodynamic therapy with Photofrin or mTHPC. [1996.05]
Response of Photofrin-sensitised mesothelioma xenografts to photodynamic therapy with 514 nm light. [1996.04]
Biological activities of phthalocyanines. XVII histopathologic evidence for different mechanisms of EMT-6 tumor necrosis induced by photodynamic therapy with disulfonated aluminum phthalocyanine or photofrin. [1996.03]
Photodynamic treatment of subcutaneous tumors in mice with photofrin II and Argon ion laser. [1996.01]
Light scattering of human skin: a comparison between zinc (II)-phthalocyanine and photofrin II. [1996.01]
Cooperative clinical trial of photodynamic therapy with photofrin II and excimer dye laser for early gastric cancer. [1996]
Dosage and timing of Photofrin for photodynamic therapy of intimal hyperplasia. [1995.10]
[Porfimer sodium (Photofrin-II)] [1995.08]
Clinical pharmacokinetic studies of photofrin by fluorescence spectroscopy in the oral cavity, the esophagus, and the bronchi. [1995.06.01]
|
